Clinical Trial Update: A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind, dose-response crossover trial evaluating two doses of EUR-1008 (APT-1008) in chronic pancreatitis with exocrine pancreatic ins…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency
• Pancreatitis

Drugs mentioned

• EUR-1008 (APT-1008) (APT-1008)

Snippet

Sponsor: Forest Laboratories | Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-03-12